NVIV logo

NVIV Free Cash Flow

Annual FCF

-$10.64 M
-$1.71 M-19.16%

December 31, 2022

Summary

Performance

1-Year Change

-19.16%

3-Year Change

-3.06%

5-Year Change

+46.11%

15-Year Change

+46.11%

NVIV Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$13.30 K

3-Year Low

-$10.64 M
NVIV annual free cash flow is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NVIV previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
NVIV next annual earnings announcement has not yet been scheduled

OtherNVIVcash flowmetrics:

Annual CFO

-$10.48 M
NVIV annual cash flow from operations is -$10.48 million

Annual CFF

$7.96 M
NVIV annual cash flow from financing activities is $7.96 million

Annual CFI

-$160.00 K
NVIV annual cash flow from investing activities is -$160.00 thousand

Annual CAPEX

-
NVIV annual capital expenditures value is unknown

Quarterly FCF

-$2.28 M
+$176.00 K+7.16%

September 30, 2023

Summary

Performance

3-Month Change

+7.16%

1-Year Change

+6.13%

3-Year Change

-18.24%

5-Year Change

+10.61%

NVIV Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$0.00
NVIV quarterly free cash flow is currently <-9900.00% below its historical high of $0.00

3-Year Low

-$3.85 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NVIV previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NVIV next earnings announcement has not yet been scheduled

OtherNVIVcash flowmetrics:

Quarterly CFO

-$2.28 M
NVIV quarterly cash flow from operations is -$2.28 million

Quarterly CFF

-
NVIV quarterly cash flow from financing activities value is unknown

Quarterly CFI

$43.00 K
NVIV quarterly cash flow from investing activities is $43.00 thousand

Quarterly CAPEX

-
NVIV quarterly capital expenditures value is unknown

TTM FCF

-$10.17 M
+$149.00 K+1.44%

September 30, 2023

Summary

Performance

3-Month Change

+1.44%

1-Year Change

+3.15%

3-Year Change

-6.76%

5-Year Change

+1.37%

NVIV TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$22.30 K

3-Year Low

-$10.64 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NVIV previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NVIV next earnings announcement has not yet been scheduled

OtherNVIVcash flowmetrics:

TTM CFO

-$10.13 M
NVIV TTM cash flow from operations is -$10.13 million

TTM CFF

-
NVIV TTM cash flow from financing activities value is unknown

TTM CFI

$50.00 K
NVIV TTM cash flow from investing activities is $50.00 thousand

TTM CAPEX

-
NVIV TTM capital expenditures value is unknown

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

-$10.64 M
NVIV annual free cash flow is -$10.64 million

Annual CFO

-$10.48 M
NVIV annual cash flow from operations is -$10.48 million

Annual CAPEX

-
NVIV annual capital expenditures value is unknown

NVIV Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-19.2%+6.1%+3.1%
3 y3 years-3.1%-18.2%-6.8%
5 y5 years+46.1%+10.6%+1.4%

NVIV Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+19.2%at low+10.2%+68.9%+13.9%+4.6%
5 y5-year+19.2%at low+34.0%+68.9%+15.7%+5.0%
alltimeall time>+9999.0%+85.6%<-9999.0%+169.8%>+9999.0%+95.3%

InVivo Therapeutics Holdings Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2023
-
-$2.28 M(-7.2%)
-$10.17 M(-1.4%)
Jun 2023
-
-$2.46 M(-23.8%)
-$10.32 M(+3.1%)
Mar 2023
-
-$3.23 M(+46.1%)
-$10.01 M(-5.9%)
Dec 2022
-$10.64 M(+19.2%)
-$2.21 M(-9.2%)
-$10.64 M(+1.3%)
Sep 2022
-
-$2.43 M(+13.2%)
-$10.50 M(+5.1%)
Jun 2022
-
-$2.15 M(-44.3%)
-$10.00 M(+4.7%)
Mar 2022
-
-$3.85 M(+86.2%)
-$9.55 M(+6.9%)
Dec 2021
-$8.93 M(-6.7%)
-$2.07 M(+7.6%)
-$8.93 M(+1.5%)
Sep 2021
-
-$1.92 M(+12.9%)
-$8.80 M(-0.1%)
Jun 2021
-
-$1.70 M(-47.4%)
-$8.80 M(-3.1%)
Mar 2021
-
-$3.23 M(+67.2%)
-$9.09 M(-5.1%)
Dec 2020
-$9.57 M(-7.3%)
-$1.94 M(+0.3%)
-$9.57 M(+0.5%)
Sep 2020
-
-$1.93 M(-2.9%)
-$9.53 M(+1.8%)
Jun 2020
-
-$1.99 M(-46.6%)
-$9.36 M(-12.3%)
Mar 2020
-
-$3.72 M(+97.0%)
-$10.68 M(+3.5%)
Dec 2019
-$10.33 M(-16.6%)
-$1.89 M(+7.2%)
-$10.31 M(-9.6%)
Sep 2019
-
-$1.76 M(-46.7%)
-$11.41 M(-6.5%)
Jun 2019
-
-$3.31 M(-1.6%)
-$12.20 M(+1.3%)
Mar 2019
-
-$3.36 M(+12.4%)
-$12.04 M(-2.7%)
Dec 2018
-$12.38 M(-37.3%)
-$2.99 M(+17.0%)
-$12.38 M(-8.3%)
Sep 2018
-
-$2.55 M(-18.8%)
-$13.50 M(-13.2%)
Jun 2018
-
-$3.14 M(-14.9%)
-$15.55 M(-10.0%)
Mar 2018
-
-$3.69 M(-10.2%)
-$17.29 M(-12.5%)
Dec 2017
-$19.75 M(+17.2%)
-$4.11 M(-10.7%)
-$19.75 M(-0.6%)
Sep 2017
-
-$4.60 M(-5.6%)
-$19.87 M(+1.2%)
Jun 2017
-
-$4.88 M(-20.8%)
-$19.63 M(+4.4%)
Mar 2017
-
-$6.16 M(+45.5%)
-$18.80 M(+11.6%)
Dec 2016
-$16.85 M(+3.1%)
-$4.23 M(-2.9%)
-$16.85 M(-6.3%)
Sep 2016
-
-$4.36 M(+7.7%)
-$17.97 M(+3.1%)
Jun 2016
-
-$4.05 M(-3.8%)
-$17.44 M(-1.1%)
Mar 2016
-
-$4.21 M(-21.5%)
-$17.63 M(+7.9%)
Dec 2015
-$16.33 M(+6.5%)
-$5.36 M(+40.0%)
-$16.33 M(+7.3%)
Sep 2015
-
-$3.83 M(-9.6%)
-$15.23 M(+4.1%)
Jun 2015
-
-$4.23 M(+45.3%)
-$14.63 M(+4.4%)
Mar 2015
-
-$2.91 M(-31.5%)
-$14.02 M(-8.6%)
Dec 2014
-$15.33 M
-$4.25 M(+31.7%)
-$15.33 M(-0.2%)
DateAnnualQuarterlyTTM
Sep 2014
-
-$3.23 M(-10.8%)
-$15.37 M(-5.6%)
Jun 2014
-
-$3.62 M(-14.4%)
-$16.27 M(-3.2%)
Mar 2014
-
-$4.23 M(-1.4%)
-$16.80 M(+7.3%)
Dec 2013
-$15.65 M(+26.8%)
-$4.29 M(+3.8%)
-$15.65 M(-0.2%)
Sep 2013
-
-$4.13 M(-0.5%)
-$15.68 M(+10.0%)
Jun 2013
-
-$4.16 M(+34.9%)
-$14.25 M(+16.6%)
Mar 2013
-
-$3.08 M(-28.6%)
-$12.22 M(-1.0%)
Dec 2012
-$12.35 M(+60.1%)
-$4.31 M(+59.6%)
-$12.35 M(+19.3%)
Sep 2012
-
-$2.70 M(+27.3%)
-$10.35 M(+14.4%)
Jun 2012
-
-$2.12 M(-33.7%)
-$9.05 M(+2.6%)
Mar 2012
-
-$3.20 M(+38.0%)
-$8.82 M(+14.4%)
Dec 2011
-$7.71 M(+175.8%)
-$2.32 M(+65.9%)
-$7.71 M(+43.1%)
Sep 2011
-
-$1.40 M(-26.1%)
-$5.39 M(+34.4%)
Jun 2011
-
-$1.89 M(-9.7%)
-$4.01 M(+86.2%)
Mar 2011
-
-$2.10 M(>+9900.0%)
-$2.15 M(+3698.2%)
Dec 2010
-$2.79 M(+3393.5%)
-
-
Sep 2010
-
-$20.60 K(-42.9%)
-$56.70 K(+22.7%)
Jun 2010
-
-$36.10 K(<-9900.0%)
-$46.20 K(-42.3%)
Mar 2010
-
$0.00(0.0%)
-$80.00 K(0.0%)
Mar 2010
-$80.00 K(+257.1%)
-
-
Dec 2009
-
$0.00(-100.0%)
-$80.00 K(-0.4%)
Sep 2009
-
-$10.10 K(-85.6%)
-$80.30 K(+6.5%)
Jun 2009
-
-$69.90 K(<-9900.0%)
-$75.40 K(+238.1%)
Mar 2009
-$22.40 K(-31.9%)
$0.00(-100.0%)
-$22.30 K(-55.6%)
Dec 2008
-
-$300.00(-94.2%)
-$50.20 K(+0.2%)
Sep 2008
-
-$5200.00(-69.0%)
-$50.10 K(+5.9%)
Jun 2008
-
-$16.80 K(-39.8%)
-$47.30 K(+43.3%)
Mar 2008
-$32.90 K(-77.5%)
-$27.90 K(>+9900.0%)
-$33.00 K(+25.0%)
Dec 2007
-
-$200.00(-91.7%)
-$26.40 K(-58.9%)
Sep 2007
-
-$2400.00(-4.0%)
-$64.30 K(-45.7%)
Jun 2007
-
-$2500.00(-88.3%)
-$118.50 K(-18.9%)
Mar 2007
-$146.10 K(+998.5%)
-$21.30 K(-44.1%)
-$146.20 K(+17.1%)
Dec 2006
-
-$38.10 K(-32.7%)
-$124.90 K(+43.9%)
Sep 2006
-
-$56.60 K(+87.4%)
-$86.80 K(+187.4%)
Jun 2006
-
-$30.20 K
-$30.20 K
Mar 2006
-$13.30 K
-
-

FAQ

  • What is InVivo Therapeutics Holdings annual free cash flow?
  • What is the all time high annual FCF for InVivo Therapeutics Holdings?
  • What is InVivo Therapeutics Holdings annual FCF year-on-year change?
  • What is InVivo Therapeutics Holdings quarterly free cash flow?
  • What is the all time high quarterly FCF for InVivo Therapeutics Holdings?
  • What is InVivo Therapeutics Holdings quarterly FCF year-on-year change?
  • What is InVivo Therapeutics Holdings TTM free cash flow?
  • What is the all time high TTM FCF for InVivo Therapeutics Holdings?
  • What is InVivo Therapeutics Holdings TTM FCF year-on-year change?

What is InVivo Therapeutics Holdings annual free cash flow?

The current annual FCF of NVIV is -$10.64 M

What is the all time high annual FCF for InVivo Therapeutics Holdings?

InVivo Therapeutics Holdings all-time high annual free cash flow is -$13.30 K

What is InVivo Therapeutics Holdings annual FCF year-on-year change?

Over the past year, NVIV annual free cash flow has changed by -$1.71 M (-19.16%)

What is InVivo Therapeutics Holdings quarterly free cash flow?

The current quarterly FCF of NVIV is -$2.28 M

What is the all time high quarterly FCF for InVivo Therapeutics Holdings?

InVivo Therapeutics Holdings all-time high quarterly free cash flow is $0.00

What is InVivo Therapeutics Holdings quarterly FCF year-on-year change?

Over the past year, NVIV quarterly free cash flow has changed by +$149.00 K (+6.13%)

What is InVivo Therapeutics Holdings TTM free cash flow?

The current TTM FCF of NVIV is -$10.17 M

What is the all time high TTM FCF for InVivo Therapeutics Holdings?

InVivo Therapeutics Holdings all-time high TTM free cash flow is -$22.30 K

What is InVivo Therapeutics Holdings TTM FCF year-on-year change?

Over the past year, NVIV TTM free cash flow has changed by +$331.00 K (+3.15%)